Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bart L Scott

Showing results (21-30 of 119) with videos related to

Pageof 12
Sort By:
BMJ Open|July 25, 2018
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United StatesXiaomei Ma, David P Steensma, Bart L Scott, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 11, 2017
Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating AgentsMoreno Festuccia, Kelsey Baker, Theodore A Gooley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 30, 2016
Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective TrialJanghee Woo, H Joachim Deeg, Barry Storer, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|November 17, 2015
The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysisBethany T Samuelson, Sara K Vesely, Chatree Chai-Adisaksopha, et al.
British Journal of Haematology|March 25, 2010
Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II studyBart L Scott, Aravind Ramakrishnan, Mark Fosdal, et al.
Blood|July 9, 2008
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndromeBart L Scott, Denise A Wells, Michael R Loken, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 4, 2019
Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of EculizumabJason P Cooper, Rafic J Farah, Philip A Stevenson, et al.
British Journal of Haematology|January 13, 2010
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanerceptBart L Scott, Aravind Ramakrishnan, Barry Storer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 24, 2007
Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasiaBart L Scott, Barry E Storer, Joanne E Greene, et al.
Bone Marrow Transplantation|September 2, 2018
Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHDArmin Rashidi, Ryan Shanley, Claudio Anasetti, et al.
Pageof 12

Showing results (21-30 of 119) with videos related to

Sort By:
Pageof 12
BMJ Open|July 25, 2018
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United StatesXiaomei Ma, David P Steensma, Bart L Scott, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 11, 2017
Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating AgentsMoreno Festuccia, Kelsey Baker, Theodore A Gooley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 30, 2016
Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective TrialJanghee Woo, H Joachim Deeg, Barry Storer, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|November 17, 2015
The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysisBethany T Samuelson, Sara K Vesely, Chatree Chai-Adisaksopha, et al.
British Journal of Haematology|March 25, 2010
Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II studyBart L Scott, Aravind Ramakrishnan, Mark Fosdal, et al.
Blood|July 9, 2008
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndromeBart L Scott, Denise A Wells, Michael R Loken, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 4, 2019
Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of EculizumabJason P Cooper, Rafic J Farah, Philip A Stevenson, et al.
British Journal of Haematology|January 13, 2010
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanerceptBart L Scott, Aravind Ramakrishnan, Barry Storer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 24, 2007
Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasiaBart L Scott, Barry E Storer, Joanne E Greene, et al.
Bone Marrow Transplantation|September 2, 2018
Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHDArmin Rashidi, Ryan Shanley, Claudio Anasetti, et al.
Pageof 12